[Neuroleptic malignant syndrome]

Medicina (Kaunas). 2002;38(1):1-5.
[Article in Lithuanian]

Abstract

The neuroleptic malignant syndrome (NMS) is a rare but potentially lethal form of neuroleptic drug-induced hyperthermia, altered level of consciousness, extrapyramidal effects, autonomic instability and muscle rigidity. The present review describes pathophysiology, frequency, course, outcome, mortality and management of NMS in prehospital care and emergency department care. Review discusses clinical features, diagnosis differentiation of this hyperpyretic-rigidity syndrome from other disorders and prevention of this serious iatrogenic condition as life-threatening disorder.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / etiology
  • Adult
  • Amantadine / administration & dosage
  • Amantadine / therapeutic use
  • Bromocriptine / administration & dosage
  • Bromocriptine / therapeutic use
  • Carbidopa / administration & dosage
  • Carbidopa / therapeutic use
  • Contraindications
  • Dantrolene / administration & dosage
  • Dantrolene / therapeutic use
  • Diagnosis, Differential
  • Dopamine Agents / administration & dosage
  • Dopamine Agents / therapeutic use
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / therapeutic use
  • Female
  • Humans
  • Intensive Care Units
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use
  • Male
  • Muscle Relaxants, Central / administration & dosage
  • Muscle Relaxants, Central / therapeutic use
  • Neuroleptic Malignant Syndrome* / complications
  • Neuroleptic Malignant Syndrome* / diagnosis
  • Neuroleptic Malignant Syndrome* / drug therapy
  • Neuroleptic Malignant Syndrome* / therapy
  • Prognosis
  • Rhabdomyolysis / etiology

Substances

  • Dopamine Agents
  • Dopamine Agonists
  • Muscle Relaxants, Central
  • Bromocriptine
  • Levodopa
  • Amantadine
  • Dantrolene
  • Carbidopa